GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (OTCPK:KDGTF) » Definitions » Debt-to-EBITDA

Kindstar Globalgene Technology (Kindstar Globalgene Technology) Debt-to-EBITDA : 2.33 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kindstar Globalgene Technology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $23.1 Mil. Kindstar Globalgene Technology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.1 Mil. Kindstar Globalgene Technology's annualized EBITDA for the quarter that ended in Dec. 2023 was $11.7 Mil. Kindstar Globalgene Technology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.33.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kindstar Globalgene Technology's Debt-to-EBITDA or its related term are showing as below:

KDGTF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -15.92   Med: -0.05   Max: 1.54
Current: 1.54

During the past 6 years, the highest Debt-to-EBITDA Ratio of Kindstar Globalgene Technology was 1.54. The lowest was -15.92. And the median was -0.05.

KDGTF's Debt-to-EBITDA is ranked better than
52.48% of 101 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.76 vs KDGTF: 1.54

Kindstar Globalgene Technology Debt-to-EBITDA Historical Data

The historical data trend for Kindstar Globalgene Technology's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology Debt-to-EBITDA Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -2.53 -0.09 -0.01 1.33 1.54

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.12 0.10 2.15 1.39 2.33

Competitive Comparison of Kindstar Globalgene Technology's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindstar Globalgene Technology's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's Debt-to-EBITDA falls into.



Kindstar Globalgene Technology Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kindstar Globalgene Technology's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(23.113 + 4.097) / 17.7
=1.54

Kindstar Globalgene Technology's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(23.113 + 4.097) / 11.674
=2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Kindstar Globalgene Technology  (OTCPK:KDGTF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Kindstar Globalgene Technology Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindstar Globalgene Technology (Kindstar Globalgene Technology) Business Description

Traded in Other Exchanges
Address
Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services. It organizes the business into nine segments, including hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, and Other segment provides Testing services for R&D projects and others and miscellaneous services.

Kindstar Globalgene Technology (Kindstar Globalgene Technology) Headlines

No Headlines